Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Herceptin

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2679-2

Synonyms

Definition

Herceptin is a recombinant humanized monoclonal antibody that selectively binds with high affinity to an extracellular domain of the HER-2 receptor tyrosine kinase and is approved by the United States Food and Drug Administration for therapeutic use in patients with early-stage and metastatic breast cancer that overexpress the HER-2 protein.

Characteristics

Approximately 20–30 % of human breast cancers overexpress the HER-2/neu receptor tyrosine kinase protein. These cancers are extremely aggressive with an increased tendency to metastasize, decreased time to disease progression, and reduced overall survival. In 1998, the United States Food and Drug Administration approved Herceptin, a monoclonal antibody targeted against an extracellular portion of HER-2, for clinical use in metastatic breast cancers that show amplification of the HER-2 oncogene...

Keywords

Breast Cancer Epidermal Growth Factor Receptor Metastatic Breast Cancer Improve Response Rate Constitutive Kinase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Baselga J, Albanell J, Molina MA et al (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16):4–11CrossRefPubMedGoogle Scholar
  2. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11:857–867CrossRefPubMedGoogle Scholar
  3. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123–138CrossRefPubMedGoogle Scholar
  4. Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280CrossRefPubMedGoogle Scholar
  5. Pegram MD, Pietras R, Bajamonde A et al (2005) Targeted therapy: wave of the future. J Clin Oncol 23:1776–1781CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Adjuvant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 75. doi: 10.1007/978-3-642-16483-5_107Google Scholar
  2. (2012) AKT. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 115. doi: 10.1007/978-3-642-16483-5_163Google Scholar
  3. (2012) Cross Talk. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1001. doi: 10.1007/978-3-642-16483-5_1384Google Scholar
  4. (2012) Endothelial Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1251. doi: 10.1007/978-3-642-16483-5_1896Google Scholar
  5. (2012) Extracellular Domain. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1362. doi: 10.1007/978-3-642-16483-5_2066Google Scholar
  6. (2012) Kinase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1943. doi: 10.1007/978-3-642-16483-5_3217Google Scholar
  7. (2012) Lapatinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1980. doi: 10.1007/978-3-642-16483-5_3277Google Scholar
  8. (2012) Leukocytes. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2028. doi: 10.1007/978-3-642-16483-5_3330Google Scholar
  9. (2012) Mitogen-Activated Protein Kinase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2336. doi: 10.1007/978-3-642-16483-5_3770Google Scholar
  10. (2012) Monoclonal Antibody. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2367. doi: 10.1007/978-3-642-16483-5_6842Google Scholar
  11. (2012) MTOR. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2384. doi: 10.1007/978-3-642-16483-5_3867Google Scholar
  12. (2012) Taxane. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3614. doi: 10.1007/978-3-642-16483-5_5689Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of PharmacologyEmory UniversityAtlantaUSA